Background

Healthcare Utilization and Costs Associated with Multiple Switching of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia
Objective Methods
.90  Index date -initial prescription fill for a first-line TKI (e.g., imatinib, dasatinib, nilotinib) during the study period  Continuous enrollment at least 90 days prior to (baseline period) through 180 days after (follow-up period) the first TKI prescription fill  No use of any study drugs (TKIs) within 90 days prior to the index date  Eligible patients were age 18 years or older -TSc-calculated over the first 6 months of third-line therapy  All baseline variables were calculated during the 90-day period prior to the first TKI prescription fill  An algorithm 9 was used to classify patients into one of three CML disease complexity groups (low, moderate, severe) based on their diagnosis codes for CML and related comorbidities during the baseline period Data Analysis  Chi-square tests (χ 2 ), Student's t test for independent samples or Kruskall Wallis (distributed as a chi-square) tests were used to test for differences at baseline  Generalized linear models (GLM) with log link and negative binomial distributions were used to test for differences between the cohorts -Baseline values were used as covariates when examining differences at first-line / first-line variables were used as covariates when examining differences at second-line  Wilcoxon signed-rank tests and Friedman tests for repeated measures were used to test for change within cohorts over successive therapy lines  This analysis was based on retrospective claims data, which are well suited for evaluating healthcare resource utilization and costs, but are typically lacking in clinical detail such as information regarding patients' hematological response to TKI therapy and reasons for switching  Information regarding patients' mutational status is not included in the dataset; therefore, patients that switched TKIs may have had the T315I mutation which is resistant to most therapies with the exception of ponatinib 10 and omacetaxine 11  Data available from these patients may not be generalizable to other populations such as the uninsured or patients outside of the U.S.
PCN58
 Examine healthcare resource utilization and costs for newly diagnosed CML patients as they switch from first-to second-to third-line TKI therapy relative to patients that remain on first-line TKI treatment. (Table 2)  Total healthcare costs were significantly higher among OSc and TSc relative to patients in the NSc  The OSc cohort experienced significantly more ER, hospital, and outpatient visits than the NSc cohort  The TSc cohort experienced significantly more hospital and outpatient visits than the OSc cohort Second-Line Therapy: Healthcare Resource Utilization and Costs (Table 3)  Total healthcare costs were significantly higher during second-line for the TSc cohort compared to the OSc cohort  TSc experienced a significantly higher number of monthly hospital and outpatient visits than the OSc cohort, but the ER visits for this cohort was not significantly higher (Table 4)  OSc and TSc cohorts experienced a significant increase in total monthly costs from first-line to second-line KI treatment  For TSC, costs at third-line decreased from second-line levels but were still significantly higher than costs during first-line  For TSc, outpatient visits significantly increased from first-line to second, but declined at third-line though still higher than what it was during first-line therapy Note. * p < .05; a medians calculated using cases with non-zero values; OSc = One-Switch Cohort; TSc Two-Switch Cohort; ER = emergency room; OP = outpatient; IR = interquartile range. 
Results
Variable
Conclusions
 In this real-world analysis, experiencing treatment failure and switching to a second-and third-line TKI was associated with substantial healthcare utilization and economic burden in CML patients  The increased cost and burden was especially true for patients who failed second-line TKI therapy, as multiple TKI switches were associated with the greater number of hospital and outpatient visits as well as the higher healthcare costs  The higher healthcare costs for patients needing to switch therapy could be related to those patients having a more active progressive disease  Future research, regarding alternative therapies, such as switching these types of patients earlier to a non-TKI and monitor their molecular response; as well as extending these findings with regard to Quality of Life and the associated humanistic burden of TKI switching on patients with CML would be valuable.
